安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- A randomized phase 3 trial of zanubrutinib vs ibrutinib in . . . - PubMed
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM) The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in pati …
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström . . .
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM) Here, we report long-term follow-up outcomes from ASPEN The primary end point was the Zanubrutinib continues to demonstrate meaningful efficacy and favorable safety in patients with WM
- Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom . . .
A higher all-cause mortality risk was observed in the ibrutinib cohort (RR 1 67, 95% C I of 1 03-2 71) with mortality rates of 10 5% in the ibrutinib cohort and 6 3% in the zanubrutinib cohort There was no statistically significant difference in the rate of initiation of a subsequent line of treatment
- Head-to-Head: Zanubrutinib vs Ibrutinib in Waldenström . . .
However, the comparison of infection rates across the ibrutinib and zanubrutinib arms were similar for all grades, (66% vs 67%, respectively) and grade 3 or higher (19 4% vs 17 8%, respectively) “The primary objective of the study was not met
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic . . .
This finding is consistent with the findings in the phase 3 ASPEN trial, which compared zanubrutinib with ibrutinib in patients with Waldenström’s macroglobulinemia 26 One hypothesis is that
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström . . .
Zanubrutinib continues to demonstrate meaningful efficacy and favorable safety in patients with WM INTRODUCTION Zanubrutinib is a potent, selective next-generation covalent Bruton tyrosine kinase inhibitor approved in several countries for Waldenström macroglobulinemia (WM) in adults 1-4 Despite not meeting its primary end point at a median follow-up of 19 4 months in ASPEN, zanubrutinib
- Long-Term Outcomes With Zanubrutinib vs Ibrutinib in Symptomatic . . .
The study supported the September 2021 approval of zanubrutinib in this setting As stated by the investigators, “The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib vs ibrutinib in patients with Waldenström’s macroglobulinemia Here, we report long-term follow-up outcomes from ASPEN ”
- Zanubrutinib in Waldenström Macroglobulinemia | Journal of Clinical . . .
The unblinded multicenter phase III ASPEN study (ClinicalTrials gov identifier: NCT03053440) compared the safety and efficacy of zanubrutinib with that of ibrutinib in advanced Waldenström macroglobulinemia 1 We raise some concerns regarding the recently published 44-month ASPEN follow-up, which we hope the authors might address
|
|
|